Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC
Автор: VJOncology
Загружено: 2025-09-08
Просмотров: 143
Описание:
Whilst findings from FLAURA2 trial (NCT04035486) were promising, osimertinib with chemotherapy is not curative. Regan Memmott, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, results from a Phase Ib trial (NCT04780568) of osimertinib with tegavivint as first-line therapy in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC). The study demonstrated that the combination was safe and well tolerated, with no dose-limiting toxicities observed. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
